- Stiripentol
-
- $75.00 / 10mg
-
2026-04-22
- CAS:49763-96-4
- Min. Order:
- Purity: 99.87%
- Supply Ability: 10g
- STIRIPENTOL USP/EP/BP
-
- $1.10 / 1g
-
2025-11-18
- CAS:49763-96-4
- Min. Order: 1g
- Purity: 99.9%
- Supply Ability: 100 Tons min
- STIRIPENTOL
-
- $714.30 / 1Kg/Bag
-
2021-11-02
- CAS:49763-96-4
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 500kg
|
| | STIRIPENTOL Basic information |
| Product Name: | STIRIPENTOL | | Synonyms: | Diacomit;(RS)-(E)-4,4-dimethyl-1-[3,4(methylenedioxy)-phenyl]-1-penten-3-ol;1-(1,3-BENZODIOXOL-5YL)-4,4-DIMETHYL-1-PENTEN-3-OL;STIRIPENTOL;1-(1,3-benzodioxol-5-yl)-4,4-dimethyl-1-penten-3-o;4,4-dimethyl-1-(3,4-methylenedioxyphenyl)-1-penten-3-o;4,4-dimethyl-1-(3,4-methylenedioxyphenyl)-1-penten-3-ol;bcx2600 | | CAS: | 49763-96-4 | | MF: | C14H18O3 | | MW: | 234.29 | | EINECS: | 256-480-9 | | Product Categories: | Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;APIs | | Mol File: | 49763-96-4.mol |  |
| | STIRIPENTOL Chemical Properties |
| Melting point | 73-74°C | | Boiling point | 365.4±11.0 °C(Predicted) | | density | 1.139±0.06 g/cm3(Predicted) | | storage temp. | -20°C | | solubility | DMSO: ≥20mg/mL | | form | powder | | pka | 14.45±0.20(Predicted) | | color | white to beige | | InChI | InChI=1S/C14H18O3/c1-14(2,3)13(15)7-5-10-4-6-11-12(8-10)17-9-16-11/h4-8,13,15H,9H2,1-3H3 | | InChIKey | IBLNKMRFIPWSOY-FNORWQNLSA-N | | SMILES | C(C1=CC=C2OCOC2=C1)=CC(O)C(C)(C)C | | CAS DataBase Reference | 49763-96-4 |
| Hazard Codes | Xn | | Risk Statements | 22 | | WGK Germany | 3 | | RTECS | SB3393000 | | HS Code | 2932.99.7000 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Acute Tox. 4 Oral |
| | STIRIPENTOL Usage And Synthesis |
| Description | Stiripentol is a third-generation antiepileptic compound. It is a positive allosteric modulator of GABAA receptors, potentiating GABA-mediated activation to a greater extent in receptors expressing α3 subunits and to a lower extent in those containing β1 or ε subunits. It also inhibits GABA reuptake in vitro and increases the release of GABA in neonatal rat hippocampal slices. Stiripentol (500 μM) inhibits lactate dehydrogenase (LDH), blocking both lactate-to-pyruvate and pyruvate-to-lactate conversions by human LDH1 and LDH5. Formulations containing stiripentol have been used in the adjunctive treatment of seizures associated with Dravet syndrome. | | Chemical Properties | White Solid | | Uses | An antiepileptic drug | | Uses | Stiripentol is an epilepsy drug, it has been used as co-therapy for treatment of epilepsy. | | Uses | Stiripentol has been used in pharmacokinetic analysis and as a reference standard in fluorescence spectra analysis. | | Definition | ChEBI: 1-(1,3-benzodioxol-5-yl)-4,4-dimethyl-1-penten-3-ol is a phenylpropanoid. | | Biochem/physiol Actions | Anti-convulsant drug | | Synthesis | A method for the preparation of Stiripentol comprising the steps of:
(1) 120g of piperonal was put into a mixed solvent of 0.2L of ethanol and 2.4L of distilled water, 160g of solid NaOH, 2.6g of benzyltributylammonium chloride and 120g of methyl tert-butyl ketone were added, and the reaction was stirred at 40C. The reaction was detected by TLC (unfolding reagent: petroleum ether- ethyl acetate (6:1)), and the reaction was complete after 16h. The reaction solution was cooled to room temperature, filtered under reduced pressure, and the filter cake was recrystallized with 0.12 L of anhydrous ethanol and dried to obtain yellow needle-like crystals of 4,4-dimethyl-1-[(3,4-methylenedioxy)-phenyl] -1-penten-3-one (172.5 g, 93.2%), m.p. 93.7-95.1 C. ESI-MS (m/z): 233.1 [M +H]+, 255.1 [M+Na]+.
(2) The 4,4-dimethyl-1-[(3,4-methylenedioxy)-phenyl]-1-pentene obtained in step (1) was -3-ketone into 0.8L of ethanol, stirring at 25 ~ 40 , within 10 minutes to add sodium borohydride 14.8g in batches, adding sodium borohydride in batches can be avoided to local concentration caused by the reaction is not uniform, and then add 0.08L of acetone and 0.12L of distilled water, stirring at 50 for 5 minutes, bubbles generated , after the bubbles disappeared, continue to add water, there is solid precipitation, after the solid precipitation is complete, cooled to room temperature, filtration under reduced pressure, the filter cake was recrystallized with 0.15L of anhydrous ethanol, drying, to obtain white crystals of stiripentol total (91.1g, 93.7%).
| | References | [1] USZCZKI J J. Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions[J]. Pharmacological Reports, 2009, 61 2: Pages 197-216. DOI: 10.1016/s1734-1140(09)70024-6
[2] FISHER J L. The anti-convulsant stiripentol acts directly on the GABAA receptor as a positive allosteric modulator[J]. Neuropharmacology, 2009, 56 1: Pages 190-197. DOI: 10.1016/j.neuropharm.2008.06.004
[3] PASCALE P. QUILICHINI. Stiripentol, a Putative Antiepileptic Drug, Enhances the Duration of Opening of GABAA-Receptor Channels[J]. Epilepsia, 2006, 47 4: 704-716. DOI: 10.1111/j.1528-1167.2006.00497.x
[4] NAGISA SADA. Targeting LDH enzymes with a stiripentol analog to treat epilepsy[J]. Science, 2015, 347 6228. DOI: 10.1126/science.aaa1299 |
| | STIRIPENTOL Preparation Products And Raw materials |
|